Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Nov;77(11):1549-1557.
doi: 10.1136/annrheumdis-2018-213512. Epub 2018 Jul 25.

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)

Bernardo A Pons-Estel #  1 Eloisa Bonfa #  2 Enrique R Soriano #  3 Mario H Cardiel #  4 Ariel Izcovich  5 Federico Popoff  5 Juan M Criniti  5 Gloria Vásquez  6 Loreto Massardo  7 Margarita Duarte  8 Leonor A Barile-Fabris  9 Mercedes A García  10 Mary-Carmen Amigo  11 Graciela Espada  12 Luis J Catoggio  3 Emilia Inoue Sato  13 Roger A Levy  14 Eduardo M Acevedo Vásquez  15 Rosa Chacón-Díaz  16 Claudio M Galarza-Maldonado  17 Antonio J Iglesias Gamarra  18 José Fernando Molina  19 Oscar Neira  20 Clóvis A Silva  21 Andrea Vargas Peña  22 José A Gómez-Puerta  23 Marina Scolnik  3 Guillermo J Pons-Estel  1   24 Michelle R Ugolini-Lopes  2 Verónica Savio  25 Cristina Drenkard  26 Alejandro J Alvarellos  27 Manuel F Ugarte-Gil  28   29 Alejandra Babini  25 André Cavalcanti  30 Fernanda Athayde Cardoso Linhares  22 Maria Jezabel Haye Salinas  27 Yurilis J Fuentes-Silva  31 Ana Carolina Montandon de Oliveira E Silva  32 Ruth M Eraso Garnica  33 Sebastián Herrera Uribe  34 Diana Gómez-Martín  35 Ricardo Robaina Sevrini  36 Rosana M Quintana  1   24 Sergio Gordon  37 Hilda Fragoso-Loyo  35 Violeta Rosario  38 Verónica Saurit  27 Simone Appenzeller  39 Edgard Torres Dos Reis Neto  13 Jorge Cieza  40 Luis A González Naranjo  6 Yelitza C González Bello  41 María Victoria Collado  42 Judith Sarano  42 Soledad Retamozo  27 María E Sattler  43 Rocio V Gamboa-Cárdenas  28 Ernesto Cairoli  36 Silvana M Conti  24 Luis M Amezcua-Guerra  44 Luis H Silveira  45 Eduardo F Borba  2 Mariana A Pera  10 Paula B Alba Moreyra  46 Valeria Arturi  10 Guillermo A Berbotto  43 Cristian Gerling  37 Carla A Gobbi  46 Viviana L Gervasoni  24 Hugo R Scherbarth  37 João C Tavares Brenol  47 Fernando Cavalcanti  30 Lilian T Lavras Costallat  39 Nilzio A Da Silva  32 Odirlei A Monticielo  47 Luciana Parente Costa Seguro  2 Ricardo M Xavier  47 Carolina Llanos  48 Rubén A Montúfar Guardado  49 Ignacio Garcia de la Torre  50 Carlos Pineda  51 Margarita Portela Hernández  52 Alvaro Danza  53 Marlene Guibert-Toledano  54 Gil Llerena Reyes  54 Maria Isabel Acosta Colman  8 Alicia M Aquino  8 Claudia S Mora-Trujillo  40 Roberto Muñoz-Louis  38 Ignacio García Valladares  41 María Celeste Orozco  55 Paula I Burgos  48 Graciela V Betancur  55 Graciela S Alarcón  56   57 Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR)
Affiliations
Practice Guideline

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR)

Bernardo A Pons-Estel et al. Ann Rheum Dis. 2018 Nov.

Abstract

Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings.

Keywords: lupus nephritis; systemic lupus erythematosus; treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LBF, BAPE and OAM have been speakers for GlaxoSmithKline (GSK). JCTB has received research grants from GSK. RMX, ON and JFM have received support grants for meetings from GSK. JAGP has been a lecturer for Roche. ERS has received research grants and has been a lecturer for Roche. JFM has been a clinical researcher for Anthera. MHC has received research grants from Roche and is an advisor for Eli Lilly.

Comment in

References

    1. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. . The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine 2004;83:1–17. 10.1097/01.md.0000104742.42401.e2 - DOI - PubMed
    1. Alarcón GS, McGwin G, Bartolucci AA, et al. . Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001;44:2797–806. 10.1002/1529-0131(200112)44:12<2797::AID-ART467>3.0.CO;2-9 - DOI - PubMed
    1. Alarcón GS, McGwin G, Bastian HM, et al. . Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001;45:191–202. 10.1002/1529-0131(200104)45:2<191::AID-ANR173>3.0.CO;2-2 - DOI - PubMed
    1. Alarcón-Segovia D, Alarcón-Riquelme ME, Cardiel MH, et al. . Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 2005;52:1138–47. 10.1002/art.20999 - DOI - PubMed
    1. Pons-Estel GJ, Alarcón GS, Scofield L, et al. . Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257–68. 10.1016/j.semarthrit.2008.10.007 - DOI - PMC - PubMed

Publication types

MeSH terms